This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.theguardian.com/society/2018/aug/27/weight-loss-drug-belviq-not-linked-to-heart-problems-finds-study
The article has changed 4 times. There is an RSS feed of changes available.
| Version 2 | Version 3 |
|---|---|
| Weight-loss pill hailed as 'holy grail' in fight against obesity | Weight-loss pill hailed as 'holy grail' in fight against obesity |
| (about 1 month later) | |
| A weight-loss pill has been hailed as a potential “holy grail” in the fight against obesity after a major study showed it did not increase the risk of serious heart problems. | A weight-loss pill has been hailed as a potential “holy grail” in the fight against obesity after a major study showed it did not increase the risk of serious heart problems. |
| Researchers say lorcaserin is the first weight-loss drug to be deemed safe for heart health with long-term use. Taken twice a day, the drug is an appetite suppressant which works by stimulating brain chemicals to induce a feeling of fullness. | Researchers say lorcaserin is the first weight-loss drug to be deemed safe for heart health with long-term use. Taken twice a day, the drug is an appetite suppressant which works by stimulating brain chemicals to induce a feeling of fullness. |
| A US study saw 12,000 people who were either obese or overweight given the pills or a placebo – with those who took the drug shedding an average of 4kg (9lbs) in 40 months. | A US study saw 12,000 people who were either obese or overweight given the pills or a placebo – with those who took the drug shedding an average of 4kg (9lbs) in 40 months. |
| Lack of sleep makes people pile on the pounds | Lack of sleep makes people pile on the pounds |
| Further analysis showed no big differences in tests for heart valve damage. | Further analysis showed no big differences in tests for heart valve damage. |
| Tam Fry, of Britain’s National Obesity Forum, said the drug is potentially the “holy grail” of weight-loss medicine. | Tam Fry, of Britain’s National Obesity Forum, said the drug is potentially the “holy grail” of weight-loss medicine. |
| “I think it is the thing everybody has been looking for,” he said. | “I think it is the thing everybody has been looking for,” he said. |
| “I think there will be several holy grails, but this is a holy grail and one which has been certainly at the back of the mind of a lot of specialists for a long time. | “I think there will be several holy grails, but this is a holy grail and one which has been certainly at the back of the mind of a lot of specialists for a long time. |
| “But all of the other things apply – lifestyle change has got to be root and branch part of this.” | “But all of the other things apply – lifestyle change has got to be root and branch part of this.” |
| Prof Jason Halford, an obesity expert at the University of Liverpool, told the Daily Telegraph newspaper that the drug’s availability in the UK would depend on whether it is approved by National Health Service regulators. | Prof Jason Halford, an obesity expert at the University of Liverpool, told the Daily Telegraph newspaper that the drug’s availability in the UK would depend on whether it is approved by National Health Service regulators. |
| “We don’t have any appetite suppressants available on the NHS. We have a massive great gap between lifestyle modification and surgery,” he said. | “We don’t have any appetite suppressants available on the NHS. We have a massive great gap between lifestyle modification and surgery,” he said. |
| “At the moment you either get support and advice, or you get to surgery - there is nothing in between. This could be widely prescribed if it is approved by Nice (the National Institute of Health and Care Excellence) in the UK.” | “At the moment you either get support and advice, or you get to surgery - there is nothing in between. This could be widely prescribed if it is approved by Nice (the National Institute of Health and Care Excellence) in the UK.” |
| The Food and Drug Administration, the US medicines watchdog, approved lorcaserin’s use in some adults in 2012. | The Food and Drug Administration, the US medicines watchdog, approved lorcaserin’s use in some adults in 2012. |
| The drug has been on sale there since 2013 under the name Belviq, where it costs $220- 290 (£155-225) a month. | The drug has been on sale there since 2013 under the name Belviq, where it costs $220- 290 (£155-225) a month. |
| The study into its long-term effects was led by Dr Erin Bohula, a cardiovascular medicine expert at the Harvard-affiliated Brigham and Women’s Hospital. | The study into its long-term effects was led by Dr Erin Bohula, a cardiovascular medicine expert at the Harvard-affiliated Brigham and Women’s Hospital. |
| “Patients and their doctors have been nervous about using drugs to treat obesity and for good reason. There’s a history of these drugs having serious complications,” she said. | “Patients and their doctors have been nervous about using drugs to treat obesity and for good reason. There’s a history of these drugs having serious complications,” she said. |
| As well as affecting the heart, there are concerns weight-loss drugs can lead to mental health issues. | As well as affecting the heart, there are concerns weight-loss drugs can lead to mental health issues. |
| The results of the study into lorcaserin were discussed at the European Society of Cardiology in Munich on Sunday and have been published by the New England Journal of Medicine. | The results of the study into lorcaserin were discussed at the European Society of Cardiology in Munich on Sunday and have been published by the New England Journal of Medicine. |
| We’re in a new age of obesity. How did it happen? You’d be surprised | George Monbiot | We’re in a new age of obesity. How did it happen? You’d be surprised | George Monbiot |
| The researchers found after one year 39% of participants given lorcaserin had lost at least 5% of their starting weight, compared with 17% of those given placebo. Analysis also showed fewer people taking lorcaserin developed diabetes, 8.5% compared with 10.3% on placebo. | The researchers found after one year 39% of participants given lorcaserin had lost at least 5% of their starting weight, compared with 17% of those given placebo. Analysis also showed fewer people taking lorcaserin developed diabetes, 8.5% compared with 10.3% on placebo. |
| Tests for heart valve damage were done on 3,270 participants, but no significant differences in rates were identified. | Tests for heart valve damage were done on 3,270 participants, but no significant differences in rates were identified. |
| Suicidal thoughts or behaviour were reported in 21 people taking lorcaserin compared with 11 people given placebo, however those taking the weight-loss drug had a history of depression. | Suicidal thoughts or behaviour were reported in 21 people taking lorcaserin compared with 11 people given placebo, however those taking the weight-loss drug had a history of depression. |
| The researchers said: “Among overweight or obese patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors who were being treated with dietary and exercise interventions, those who received lorcaserin had better long-term rates of weight loss than those who received placebo at a median follow-up of 3.3 years. | The researchers said: “Among overweight or obese patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors who were being treated with dietary and exercise interventions, those who received lorcaserin had better long-term rates of weight loss than those who received placebo at a median follow-up of 3.3 years. |
| “The higher weight-loss rates were achieved without an accompanying increase in the risk of cardiovascular events.” | “The higher weight-loss rates were achieved without an accompanying increase in the risk of cardiovascular events.” |
| Obesity | Obesity |
| Diets and dieting | Diets and dieting |
| Health | Health |
| Medical research | Medical research |
| Health & wellbeing | Health & wellbeing |
| news | news |
| Share on Facebook | Share on Facebook |
| Share on Twitter | Share on Twitter |
| Share via Email | Share via Email |
| Share on LinkedIn | Share on LinkedIn |
| Share on Pinterest | Share on Pinterest |
| Share on WhatsApp | Share on WhatsApp |
| Share on Messenger | Share on Messenger |
| Reuse this content | Reuse this content |